Literature DB >> 25820332

Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma.

Yasuhiro Oki1, Anas Younes2, Javier Knickerbocker2, Felipe Samaniego2, Loretta Nastoupil2, Fredrick Hagemeister2, Jorge Romaguera2, Nathan Fowler2, Larry Kwak2, Jason Westin2.   

Abstract

Entities:  

Keywords:  clinical trial; heat shock protein; lymphoma; targeted therapy

Mesh：

Substances：

Year:  2015        PMID： 25820332      PMCID： PMC4486240          DOI： 10.3324/haematol.2015.126557

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.

Authors:  Udai Banerji; Anne O'Donnell; Michelle Scurr; Simon Pacey; Sarah Stapleton; Yasmin Asad; Laura Simmons; Alison Maloney; Florence Raynaud; Maeli Campbell; Michael Walton; Sunil Lakhani; Stanley Kaye; Paul Workman; Ian Judson
Journal:  J Clin Oncol       Date:  2005-06-20       Impact factor: 44.544

2.  Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.

Authors:  Matthew P Goetz; David Toft; Joel Reid; Matthew Ames; Bridget Stensgard; Stephanie Safgren; Araba A Adjei; Jeff Sloan; Pamela Atherton; Vlad Vasile; Sandra Salazaar; Alex Adjei; Gary Croghan; Charles Erlichman
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

3.  Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.

Authors:  Jean L Grem; Geraldine Morrison; Xiao-Du Guo; Elizabeth Agnew; Chris H Takimoto; Rebecca Thomas; Eva Szabo; Louise Grochow; Frank Grollman; J Michael Hamilton; Len Neckers; Richard H Wilson
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

4.  Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.

Authors:  Martin Kaiser; Britta Lamottke; Maren Mieth; Michael R Jensen; Cornelia Quadt; Carlos Garcia-Echeverria; Peter Atadja; Ulrike Heider; Ivana von Metzler; Seval Türkmen; Orhan Sezer
Journal:  Eur J Haematol       Date:  2009-12-17       Impact factor: 2.997

Review 5.  Targeting the dynamic HSP90 complex in cancer.

Authors:  Jane Trepel; Mehdi Mollapour; Giuseppe Giaccone; Len Neckers
Journal:  Nat Rev Cancer       Date:  2010-08       Impact factor: 60.716

6.  DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.

Authors:  L R Kelland; S Y Sharp; P M Rogers; T G Myers; P Workman
Journal:  J Natl Cancer Inst       Date:  1999-11-17       Impact factor: 13.506

7.  Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.

Authors:  P N Münster; A Basso; D Solit; L Norton; N Rosen
Journal:  Clin Cancer Res       Date:  2001-08       Impact factor: 12.531

8.  HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.

Authors:  Rekha Rao; Warren Fiskus; Yonghua Yang; Pearl Lee; Rajeshree Joshi; Pravina Fernandez; Aditya Mandawat; Peter Atadja; James E Bradner; Kapil Bhalla
Journal:  Blood       Date:  2008-06-30       Impact factor: 22.113

9.  NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.

Authors:  Suzanne A Eccles; Andy Massey; Florence I Raynaud; Swee Y Sharp; Gary Box; Melanie Valenti; Lisa Patterson; Alexis de Haven Brandon; Sharon Gowan; Frances Boxall; Wynne Aherne; Martin Rowlands; Angela Hayes; Vanessa Martins; Frederique Urban; Kathy Boxall; Chrisostomos Prodromou; Laurence Pearl; Karen James; Thomas P Matthews; Kwai-Ming Cheung; Andrew Kalusa; Keith Jones; Edward McDonald; Xavier Barril; Paul A Brough; Julie E Cansfield; Brian Dymock; Martin J Drysdale; Harry Finch; Rob Howes; Roderick E Hubbard; Alan Surgenor; Paul Webb; Mike Wood; Lisa Wright; Paul Workman
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

10.  NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.

Authors:  Michael Rugaard Jensen; Joseph Schoepfer; Thomas Radimerski; Andrew Massey; Chantale T Guy; Josef Brueggen; Cornelia Quadt; Alan Buckler; Robert Cozens; Martin J Drysdale; Carlos Garcia-Echeverria; Patrick Chène
Journal:  Breast Cancer Res       Date:  2008-04-22       Impact factor: 6.466
View more
  6 in total

1.  Hsp90 chaperones hemoglobin maturation in erythroid and nonerythroid cells.

Authors:  Arnab Ghosh; Greer Garee; Elizabeth A Sweeny; Yukio Nakamura; Dennis J Stuehr
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-22       Impact factor: 11.205

Review 2.  HSP90 Inhibition and Modulation of the Proteome: Therapeutical Implications for Idiopathic Pulmonary Fibrosis (IPF).

Authors:  Ruben Manuel Luciano Colunga Biancatelli; Pavel Solopov; Betsy Gregory; John D Catravas
Journal:  Int J Mol Sci       Date:  2020-07-25       Impact factor: 5.923

Review 3.  Block-And-Lock Strategies to Cure HIV Infection.

Authors:  Gerlinde Vansant; Anne Bruggemans; Julie Janssens; Zeger Debyser
Journal:  Viruses       Date:  2020-01-10       Impact factor: 5.048

Review 4.  Heat Shock Proteins in Lymphoma Immunotherapy.

Authors:  Zarema Albakova; Yana Mangasarova; Alexander Sapozhnikov
Journal:  Front Immunol       Date:  2021-03-18       Impact factor: 7.561

5.  Elucidation of the Molecular Pathways Involved in the Protective Effects of AUY-922 in LPS-Induced Inflammation in Mouse Lungs.

Authors:  Mohammad S Akhter; Mohammad A Uddin; Khadeja-Tul Kubra; Nektarios Barabutis
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-29

6.  Heat-activated nanomedicine formulation improves the anticancer potential of the HSP90 inhibitor luminespib in vitro.

Authors:  Brittany Epp-Ducharme; Michael Dunne; Linyu Fan; James C Evans; Lubabah Ahmed; Pauric Bannigan; Christine Allen
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.